EriodictyolCAS# 552-58-9 |
- (+/-)-Eriodictyol
Catalog No.:BCN0319
CAS No.:4049-38-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 552-58-9 | SDF | Download SDF |
PubChem ID | 440735 | Appearance | Powder |
Formula | C15H12O6 | M.Wt | 288.25 |
Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
Solubility | DMSO : 125 mg/mL (433.65 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | (2S)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydrochromen-4-one | ||
SMILES | C1C(OC2=CC(=CC(=C2C1=O)O)O)C3=CC(=C(C=C3)O)O | ||
Standard InChIKey | SBHXYTNGIZCORC-ZDUSSCGKSA-N | ||
Standard InChI | InChI=1S/C15H12O6/c16-8-4-11(19)15-12(20)6-13(21-14(15)5-8)7-1-2-9(17)10(18)3-7/h1-5,13,16-19H,6H2/t13-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Eriodictyol has vasodilator, anti-inflammatory and antioxidant activities, it is an antagonist of the transient potential vanilloid 1 receptor (TRPV1) receptor. Eriodictyol may possess antidiabetic properties through increasing glucose uptake and improving insulin resistance, it attenuates the degree of retinal inflammation and plasma lipid peroxidation preserving the blood-retinal barrier (BRB) in early diabetic rats. It may be a potential therapeutic resource for Atopic dermatitis and an adjunctive agent to control itchiness inAtopic dermatitis. |
Targets | COX | TLR | gp120/CD4 | p38MAPK | ERK | JNK | ROS | IL Receptor | PPAR | PI3K | Akt | TNF-α | VEGFR | NOS | TRPV | EGFR | MEK | ERK |
In vitro | Binding model for eriodictyol to Jun-N terminal kinase and its anti-inflammatory signaling pathway.[Pubmed: 24195792]BMB Rep. 2013 Dec;46(12):594-9.The anti-inflammatory activity of Eriodictyol and its mode of action were investigated.
The anti-apoptotic and anti-oxidant effect of eriodictyol on UV-induced apoptosis in keratinocytes.[Pubmed: 17202655]Biol Pharm Bull. 2007 Jan;30(1):32-7.Recently, considerable scientific and therapeutic interest has focused on the structure and functions of the flavonoids. In a previous study, we suggested that hydroxyl (OH) substitutions on specific carbons in the skeleton of the flavonoids might significantly affect their apoptosis-modulating properties.
|
In vivo | Effect of eriodictyol on the development of atopic dermatitis-like lesions in ICR mice.[Pubmed: 23902981]Biol Pharm Bull. 2013;36(8):1375-9.Atopic dermatitis (AD) is a chronic, allergic, and inflammatory skin disease associated with eczema and dermatitis symptoms. Our previous studies have reported that Eriodictyol extract inhibits immunoglobulin E (IgE)/Ag-induced type I hypersensitivity by suppressing the activation of proinflammatory cytokines, such as interleukin-4 (IL-4), and the expression of ceramide kinase.
Eriodictyol prevents early retinal and plasma abnormalities in streptozotocin-induced diabetic rats.[Pubmed: 22484312 ]Biochem Pharmacol. 2012 Jul 1;84(1):88-92.Diabetic retinopathy is a complex disease that has potential involvement of inflammatory and oxidative stress-related pathways in its pathogenesis. We hypothesized that Eriodictyol, one of the most abundant dietary flavonoids, could be effective against diabetic retinopathy, which involves significant oxidative stress and inflammation.
|
Kinase Assay | Eriodictyol inhibits RSK2-ATF1 signaling and suppresses EGF-induced neoplastic cell transformation.[Pubmed: 21098035]Eriodictyol: a flavonoid antagonist of the TRPV1 receptor with antioxidant activity.[Pubmed: 21087598 ]Biochem Pharmacol. 2011 Feb 15;81(4):544-51.The transient potential vanilloid 1 receptor (TRPV1) is a calcium-permeable channel responsible for the transduction and modulation of acute and chronic pain signaling. As such, this receptor is a potential target for the treatment of a number of pain disorders. However, AMG517, a TRPV1 antagonist, presents several clinical limitations that include the induction of severe hyperthermia.
J Biol Chem. 2011 Jan 21;286(3):2057-66.RSK2 is a widely expressed serine/threonine kinase, and its activation enhances cell proliferation.
|
Cell Research | Effect of eriodictyol on glucose uptake and insulin resistance in vitro.[Pubmed: 22809065]J Agric Food Chem. 2012 Aug 8;60(31):7652-8.Eriodictyol [2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydrochromen-4-one] is a flavonoid with anti-inflammatory and antioxidant activities.
|
Animal Research | Vasodilatory effect in rat aorta of eriodictyol obtained from Satureja obovata.[Pubmed: 10232068]Planta Med. 1999 Apr;65(3):234-8.
|
Eriodictyol Dilution Calculator
Eriodictyol Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.4692 mL | 17.3461 mL | 34.6921 mL | 69.3842 mL | 86.7303 mL |
5 mM | 0.6938 mL | 3.4692 mL | 6.9384 mL | 13.8768 mL | 17.3461 mL |
10 mM | 0.3469 mL | 1.7346 mL | 3.4692 mL | 6.9384 mL | 8.673 mL |
50 mM | 0.0694 mL | 0.3469 mL | 0.6938 mL | 1.3877 mL | 1.7346 mL |
100 mM | 0.0347 mL | 0.1735 mL | 0.3469 mL | 0.6938 mL | 0.8673 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Isorhoifolin
Catalog No.:BCN5739
CAS No.:552-57-8
- Paeonol
Catalog No.:BCN5738
CAS No.:552-41-0
- Oxohydrastinine
Catalog No.:BCN3299
CAS No.:552-29-4
- Kaempferol 3-sophoroside-7-glucoside
Catalog No.:BCN7825
CAS No.:55136-76-0
- (S)-3-Carboxy-4-hydroxyphenylglycine
Catalog No.:BCC6607
CAS No.:55136-48-6
- 4beta-Carboxy-19-nortotarol
Catalog No.:BCN4065
CAS No.:55102-39-1
- 2'-Aminoacetophenone
Catalog No.:BCN1746
CAS No.:551-93-9
- Dimetridazole
Catalog No.:BCC8944
CAS No.:551-92-8
- Supinine
Catalog No.:BCN1952
CAS No.:551-58-6
- Viridiflorine
Catalog No.:BCN2045
CAS No.:551-57-5
- 6-Aminopenicillanic acid
Catalog No.:BCC8765
CAS No.:551-16-6
- Liquiritin
Catalog No.:BCN5944
CAS No.:551-15-5
- Prunetin
Catalog No.:BCN2335
CAS No.:552-59-0
- Daidzin
Catalog No.:BCN5891
CAS No.:552-66-9
- Sasapyrine
Catalog No.:BCC4714
CAS No.:552-94-3
- Dexamethasone Sodium Phosphate
Catalog No.:BCC4557
CAS No.:55203-24-2
- AP 18
Catalog No.:BCC7634
CAS No.:55224-94-7
- Rolapitant
Catalog No.:BCC6441
CAS No.:552292-08-7
- Vallesiachotamine
Catalog No.:BCN3548
CAS No.:5523-37-5
- T16Ainh - A01
Catalog No.:BCC6220
CAS No.:552309-42-9
- A-443654
Catalog No.:BCC1321
CAS No.:552325-16-3
- A-674563
Catalog No.:BCC3903
CAS No.:552325-73-2
- Boc-Gln(Xan)-OH
Catalog No.:BCC3385
CAS No.:55260-24-7
- MnTBAP Chloride
Catalog No.:BCC6477
CAS No.:55266-18-7
Eriodictyol prevents early retinal and plasma abnormalities in streptozotocin-induced diabetic rats.[Pubmed:22484312]
Biochem Pharmacol. 2012 Jul 1;84(1):88-92.
Diabetic retinopathy is a complex disease that has potential involvement of inflammatory and oxidative stress-related pathways in its pathogenesis. We hypothesized that Eriodictyol, one of the most abundant dietary flavonoids, could be effective against diabetic retinopathy, which involves significant oxidative stress and inflammation. The aim of the present study was to investigate the effects of Eriodictyol in early retinal and plasma changes of streptozotocin-induced diabetic rats. The effect of Eriodictyol treatment (0.1, 1, 10 mg/kg daily for 10 days) was evaluated by TNF-alpha, ICAM-1, VEGF, and eNOS protein levels measurement in the retina, plasma lipid peroxidation, and blood-retinal barrier (BRB) integrity. Increased amounts of cytokines, adhesion molecule, and nitric oxide synthase were observed in retina from diabetic rats. Eriodictyol treatment significantly lowered retinal TNF-alpha, ICAM-1, VEGF, and eNOS in a dose-dependent manner. Further, treatment with Eriodictyol significantly suppressed diabetes-related lipid peroxidation, as well as the BRB breakdown. These data demonstrated that Eriodictyol attenuates the degree of retinal inflammation and plasma lipid peroxidation preserving the BRB in early diabetic rats.
Binding model for eriodictyol to Jun-N terminal kinase and its anti-inflammatory signaling pathway.[Pubmed:24195792]
BMB Rep. 2013 Dec;46(12):594-9.
The anti-inflammatory activity of Eriodictyol and its mode of action were investigated. Eriodictyol suppressed tumor necrosis factor (mTNF)-alpha, inducible nitric oxide synthase (miNOS), interleukin (mIL)-6, macrophage inflammatory protein (mMIP)-1, and mMIP-2 cytokine release in LPS-stimulated macrophages. We found that the anti-inflammatory cascade of Eriodictyol is mediated through the Toll-like Receptor (TLR)4/CD14, p38 mitogen-activated protein kinases (MAPK), extracellular-signal-regulated kinase (ERK), Jun-N terminal kinase (JNK), and cyclooxygenase (COX)-2 pathway. Fluorescence quenching and saturation-transfer difference (STD) NMR experiments showed that Eriodictyol exhibits good binding affinity to JNK, 8.79 x 10(5) M(-1). Based on a docking study, we propose a model of Eriodictyol and JNK binding, in which Eriodictyol forms 3 hydrogen bonds with the side chains of Lys55, Met111, and Asp169 in JNK, and in which the hydroxyl groups of the B ring play key roles in binding interactions with JNK. Therefore, Eriodictyol may be a potent anti-inflammatory inhibitor of JNK.
Eriodictyol inhibits RSK2-ATF1 signaling and suppresses EGF-induced neoplastic cell transformation.[Pubmed:21098035]
J Biol Chem. 2011 Jan 21;286(3):2057-66.
RSK2 is a widely expressed serine/threonine kinase, and its activation enhances cell proliferation. Here, we report that ATF1 is a novel substrate of RSK2 and that RSK2-ATF1 signaling plays an important role in EGF-induced neoplastic cell transformation. RSK2 phosphorylated ATF1 at Ser-63 and enhanced ATF1 transcriptional activity. Docking experiments using the crystal structure of the RSK2 N-terminal kinase domain combined with in vitro pulldown assays demonstrated that Eriodictyol, a flavanone found in fruits, bound with the N-terminal kinase domain of RSK2 to inhibit RSK2 N-terminal kinase activity. In cells, Eriodictyol inhibited phosphorylation of ATF1 but had no effect on the phosphorylation of RSK, MEK1/2, ERK1/2, p38 or JNKs, indicating that Eriodictyol specifically suppresses RSK2 signaling. Furthermore, Eriodictyol inhibited RSK2-mediated ATF1 transactivation and tumor promoter-induced transformation of JB6 Cl41 cells. Eriodictyol or knockdown of RSK2 or ATF1 also suppressed Ras-mediated focus formation. Overall, these results indicate that RSK2-ATF1 signaling plays an important role in neoplastic cell transformation and that Eriodictyol is a novel natural compound for suppressing RSK2 kinase activity.
Eriodictyol: a flavonoid antagonist of the TRPV1 receptor with antioxidant activity.[Pubmed:21087598]
Biochem Pharmacol. 2011 Feb 15;81(4):544-51.
The transient potential vanilloid 1 receptor (TRPV1) is a calcium-permeable channel responsible for the transduction and modulation of acute and chronic pain signaling. As such, this receptor is a potential target for the treatment of a number of pain disorders. However, AMG517, a TRPV1 antagonist, presents several clinical limitations that include the induction of severe hyperthermia. The aim of this study was to investigate the possible interaction of the flavonoid Eriodictyol with the TRPV1 receptor and to determine its putative antinociceptive and hyperthermic effects. Eriodictyol was able to displace [(3)H]-resiniferatoxin binding (IC(50)=47; 21-119nM) and to inhibit calcium influx mediated by capsaicin (IC(50)=44; 16-125nM), suggesting that Eriodictyol acts as a TRPV1 antagonist. Moreover, Eriodictyol induced antinociception in the intraplantar capsaicin test, with maximal inhibition of 49+/-10 and 64+/-4% for oral (ID(50)=2.3; 1.1-5.7mg/kg) and intrathecal (ID(50)=2.2; 1.7-2.9nmol/site) administration, respectively. Eriodictyol did not induce any change in body temperature or locomotor activity. Orally administered Eriodictyol (4.5mg/kg) prevented the nociception induced by intrathecal injections of capsaicin, as well as the non-protein thiol loss and 3-nitrotyrosine (3-NT) formation induced by capsaicin in spinal cord. Eriodictyol also reduced the thermal hyperalgesia and mechanical allodynia elicited by complete Freund's adjuvant (CFA) paw injection. In conclusion, Eriodictyol acts as an antagonist of the TRPV1 receptor and as an antioxidant; it induces antinociception without some of the side effects and limitations such as hyperthermia that are expected for TRPV1 antagonists.
Effect of eriodictyol on the development of atopic dermatitis-like lesions in ICR mice.[Pubmed:23902981]
Biol Pharm Bull. 2013;36(8):1375-9.
Atopic dermatitis (AD) is a chronic, allergic, and inflammatory skin disease associated with eczema and dermatitis symptoms. Our previous studies have reported that Eriodictyol extract inhibits immunoglobulin E (IgE)/Ag-induced type I hypersensitivity by suppressing the activation of proinflammatory cytokines, such as interleukin-4 (IL-4), and the expression of ceramide kinase. In this study, we investigated the inhibitory effect of Eriodictyol on 2,4-dinitrochlorobenzene (DNCB)-induced AD-like skin lesions in ICR mice. Treatment with 2 mg/mL Eriodictyol for DNCB-induced AD-like skin lesions in ICR mice improved scratching behavior and skin severity score. Histological analysis demonstrated that thickening of the skin lesions were significantly reduced in the Eriodictyol-treated group. Also, Eriodictyol suppressed the DNCB-mediated elevation of IgE serum levels. These results suggest that Eriodictyol may be a potential therapeutic resource for AD and an adjunctive agent to control itchiness in AD.
Effect of eriodictyol on glucose uptake and insulin resistance in vitro.[Pubmed:22809065]
J Agric Food Chem. 2012 Aug 8;60(31):7652-8.
Eriodictyol [2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydrochromen-4-one] is a flavonoid with anti-inflammatory and antioxidant activities. Because inflammation and oxidative stress play critical roles in the pathogenesis of diabetes mellitus, the present study was designed to explore whether Eriodictyol has therapeutic potential for the treatment of type 2 diabetes. The results show that Eriodictyol increased insulin-stimulated glucose uptake in both human hepatocellular liver carcinoma cells (HepG2) and differentiated 3T3-L1 adipocytes under high-glucose conditions. Eriodictyol also up-regulated the mRNA expression of peroxisome proliferator-activated receptor gamma2 (PPARgamma2) and adipocyte-specific fatty acid-binding protein (aP2) as well as the protein levels of PPARgamma2 in differentiated 3T3-L1 adipocytes. Furthermore, it reactivated Akt in HepG2 cells with high-glucose-induced insulin resistance. This response was strongly inhibited by pretreatment with the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002, indicating that Eriodictyol increased Akt phosphorylation by activating the PI3K/Akt pathway. These results imply that Eriodictyol can increase glucose uptake and improve insulin resistance, suggesting that it may possess antidiabetic properties.
Vasodilatory effect in rat aorta of eriodictyol obtained from Satureja obovata.[Pubmed:10232068]
Planta Med. 1999 Apr;65(3):234-8.
The vasodilator effect of Eriodictyol (5,7,3',4'-tetrahydroxyflavanone), isolated previously from the medicinal plant Satureja obovata Lag., was studied in rat thoracic aorta rings. Eriodictyol relaxed in a concentration-dependent manner the noradrenaline (10(-6) M) and KCl (80 mM) induced contractions. The relaxant effect was more potent in noradrenaline precontracted preparations (IC50 = 6.11 +/- 0.2 x 10(-5) M) than in those precontracted with KCl (IC50 = 2.96 +/- 0.1 x 10(-4) M). Eriodictyol produced weakly concentration-dependent inhibition of the phasic component induced by KCl and noradrenaline while the inhibition of the tonic phase of these contractions was more pronounced. These effects were endothelium independent. In addition, Eriodictyol (10(-5) and 5 x 10(-5) M) inhibited CaCl2 cumulative concentration response curves. Eriodictyol weakly inhibited the release of calcium from the sarcoplasmic reticulum and its contribution to the relaxant effect seems to be slight. We have also observed the relaxant effect of Eriodictyol on phorbol-12-myristate-13-acetate (PMA) (10(-7) M) induced contractions both in normal calcium (IC50 = 4.69 +/- 0.3 x 10(-5) M) and calcium-free medium (IC50 = 3.74 +/- 0.4 x 10(-5) M). Finally we studied the effects on protein kinase C (PKC) activity. This flavonoid did not show any activity. These results suggest that the vasodilator effect of Eriodictyol in rat thoracic aorta could be partially related to the inhibition of calcium influx or other enzymatic protein subsequent to activation of PKC related to the activation of contractile proteins like myosin light chain kinase (MLCK).
The anti-apoptotic and anti-oxidant effect of eriodictyol on UV-induced apoptosis in keratinocytes.[Pubmed:17202655]
Biol Pharm Bull. 2007 Jan;30(1):32-7.
Recently, considerable scientific and therapeutic interest has focused on the structure and functions of the flavonoids. In a previous study, we suggested that hydroxyl (OH) substitutions on specific carbons in the skeleton of the flavonoids might significantly affect their apoptosis-modulating properties. Here, to investigate the effect of various OH substitutions on their diphenylpropane (C6C3C6) skeleton carbons, we selected 10 different flavonoids and assessed their role on UV-induced apoptosis of human keratinocytes, the principal cell type of epidermis. The results showed that 5,7,3',4'-tetrahydroxylflavanone (Eriodictyol) and 3,4'-dihydroxy flavone (3,4'-DHF) had a positive effect on cell proliferation of human HaCaT keratinocytes. Treatment with Eriodictyol in particular resulted in significant suppression of cell death induced by ultraviolet (UV) light, a major skin-damaging agent. We found that Eriodictyol treatment apparently reduced the percentage of apoptotic cells and the cleavage of poly(ADP-ribose) polymerase, concomitant with the repression of caspase-3 activation and reactive oxygen species (ROS) generation. The anti-apoptotic and anti-oxidant effects of Eriodictyol were also confirmed in UV-induced cell death of normal human epidermal keratinocyte (NHEK) cells. Taken together, these findings suggest that Eriodictyol can be used to protect keratinocytes from UV-induced damage, implying the presence of a complex structure-activity relationship (SAR) in the differential apoptosis-modulating activities of various flavonoids.